June 25, 2021
Eisai and Biogen said on June 23 that their anti-amyloid beta (Aβ) protofibril antibody lecanemab, otherwise known as BAN2401, won the US FDA’s Breakthrough Therapy designation for the treatment of Alzheimer’s disease (AD). The designation was supported by data from...read more